iCellate Medical AB
Entity

  • iCellate Medical AB

    Created in 2011
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups

  • Social networks

    1,959

  • Activities

    deeptech biotech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Industrivägen 1, 171 48 Solna, Sweden

    Solna

    Sweden

  • Employees

    Scale: 11-50

    Estimated: 19

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    10 months, 3 weeks ago
Description
  • Value proposition

    Cancer profiling for precision oncology and early cancer detection

    iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing.

    Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors

  • iCellate - Cancer diagnostics via liquid biopsy

    Cancer profiling for precision oncology. Information is only as good as how we act on it. iCellate develops tools for clinical decision making, helping providers do right by their patients.

    • https://icellate.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics